Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Short-term Investments: 2017-2024

Historic Short-term Investments for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Dec 2024 value amounting to $2.0 million.

  • Lineage Cell Therapeutics' Short-term Investments fell 99.54% to $23,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $23,000, marking a year-over-year decrease of 99.54%. This contributed to the annual value of $2.0 million for FY2024, which is 3932.00% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Short-term Investments stood at $2.0 million for FY2024, which was up 3,932.00% from $50,000 recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Short-term Investments peaked at $46.5 million during FY2022, and registered a low of $50,000 during FY2023.
  • Over the past 3 years, Lineage Cell Therapeutics' median Short-term Investments value was $2.0 million (recorded in 2024), while the average stood at $16.2 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 99.89% in 2023, then surged by 3,932.00% in 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' Short-term Investments (Yearly) stood at $9.0 million in 2020, then plummeted by 70.86% to $2.6 million in 2021, then soared by 1,678.29% to $46.5 million in 2022, then crashed by 99.89% to $50,000 in 2023, then soared by 3,932.00% to $2.0 million in 2024.